FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer Grail

  • 📰 WSJ
  • ⏱ Reading Time:
  • 6 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 63%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

The FTC rejected Illumina’s $7 billion deal for Grail, saying the combination would hurt competition for cancer-detection tests while raising prices

The agency said the combination would hurt competition for cancer-detection tests while raising prices.

The agency said the combination would hurt competition for cancer-detection tests while raising prices
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

🎉🎉🥳🪅🪅🥳🥳🥳🥳🥳

Awesome! We finally have people at FTC doing what it takes to preserve competition. Biz school grads will now have to figure out how to make things work in truly competetive markets. The long run benefits of this new dynamic are so valuable.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in HEALTH

Health Health Latest News, Health Health Headlines